Overview

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

Status:
Terminated

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

Summary

Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression

Phase:

Phase 2

Details

Lead Sponsor:

Celgene Corporation

Collaborator:

Prologue Research International

Treatments:

Androgens
Lenalidomide